Aktie A2PH5Q VIVA BIOTECH HOLDINGS
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Viva Biotech Holdings

Aktien

A2PH5Q

KYG9390W1015

1873

Verzögert Hong Kong S.E.
Andere Börsenplätze
 04:41:05 10.05.2024 		% 5 Tage % 1. Jan.
0,59 HKD 0,00 % Intraday Chart für Viva Biotech Holdings -3,28 % -43,81 %
28.03. Viva Biotech Holdings meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
18.01. Viva Biotech Holdings ernennt WANG Stephen Hui zum nicht-geschäftsführenden Direktor CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023
Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director
VIVA Biotech Redeems $280 Million Convertible Bonds Ahead of 2025 Maturity
VIVA Biotech Sells 2.3% Stake in Viva Biotech (Shanghai)
VIVA Biotech Disposes of Minority Stake in Subsidiary for $15 Million
Viva Biotech Holdings Announces Executive Changes
Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer
Viva Biotech Buys Back $143.4 Million Convertible Bonds
Viva Biotech Buys Back $56.3 Million of Convertible Bonds Due 2025
Viva Biotech Disposes 24% Stake in Subsidiary
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) completed the acquisition of an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings.
Viva Biotech Completes Post-Issue Regulatory Filing for Convertible Bonds
Viva Biotech Buys Back $43 Million of 1% Convertible Bonds
Viva Biotech Holdings commences an Equity Buyback Plan for 193,503,680 shares, representing 10% of its issued share capital, under the authorization approved on June 30, 2023.
Viva Biotech Logs 64% Jump in H1 Profit
Viva Biotech Announces 2023 Interim Results Solid Growth in Main Business, Significant Rebound in Profitability
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Viva Biotech Holdings Reports Earnings Results for the Half Year Ended June 30, 2023
Viva Biotech to Swing to H1 Profit
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PH5Q Aktie
  4. Nachrichten Viva Biotech Holdings
  5. Andere Sprachen